Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Stanford, California 94305


Purpose:

The primary purpose of this study is to evaluate the ability of oral triamcinalone given twice a day to patients with androgen independent prostate cancer to produce a sustained biochemical response. Secondary goals are to describe the safety and tolerability at this dose and schedule, to determine the time to sustained biochemical response, to determine the duration of biochemical response, to determine the time to disease progression.


Criteria:

Inclusion Criteria: - 18 years of age and older - Histologically documented adenocarcinoma of prostate - Currently receiving LHRH agonists with castrate levels of testosterone or who have had an orchiectomy - Must have had a rise in PSA despite anti androgen withdrawal - Exhibit 2 consecutive rise in PSA after the last hormonal manipulation - Minimum PSA of greater than 5 KPS greater than 80% - Normal cortisol level at entry - Life expectancy greater than 6 months - Provide written consent pursuant to regulatory requirements prior to initiation of study procedure Exclusion criteria: - Younger than 18 years - Patients without prostate cancer


NCT ID:

NCT00186108


Primary Contact:

Principal Investigator
Sandy Srinivas, MD
Stanford University


Backup Contact:

N/A


Location Contact:

Stanford, California 94305
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: October 09, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.